AC Immune
Dr. Rongère joined AC Immune S.A. in July 2017 as Head of European Regulatory Affairs and Quality Assurance. Prior to AC Immune, Dr.Rongère held positions of increasing responsibility at Celgene in Switzerland. Most recently, he served as Director, Regulatory Affairs, leading the development of regulatory strategies for small molecules and CAR-T cell therapies and contributed to the development and approval of Revlimid in Multiple Myeloma and Mantle Cell Lymphoma. Prior to Celgene, he served as a Regulatory Expert at Apoxis, S.A. in Switzerland. During his career, Dr.Rongère gained specific expertise in the development of regulatory strategies for taking products from Phase 1 through to commercialization in the field of hematology/oncology and immunology/inflammation, including fast to market approaches, orphan drugs and pediatric development. Dr.Rongère gained his Masters Degree in Medical Genetics from the University of Aberdeen, UK, and holds a PhD in Molecular Biology from the University of Lausanne, Switzerland.
This person is not in any offices
AC Immune
3 followers
AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen™ and Morphomer™, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features nine therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.